Keratocytes promote corneal neovascularization through VEGFr3 induced by PPARα-inhibition

Xue Wang1, Liying Tang2, Zhaoqiang Zhang2

  • 1Aier School of Ophthalmology, Central South University, Changsha, 410015, China; Eye Institute of Xiamen University, Fujian Provincial Key Laboratory of Ophthalmology and Visual Science, Medical College, Xiamen University, Xiamen, Fujian, China.

Experimental Eye Research
|February 25, 2020
PubMed

Insights

Fenofibrate activates peroxisome proliferator-activated receptor alpha (PPARα), inhibiting corneal neovascularization (CNV). This study reveals PPARα downregulation promotes CNV by increasing VEGFr3 and MMP13 expression in keratocytes.

Area of Science:

  • Ophthalmology
  • Molecular Biology
  • Pharmacology

Background:

  • Corneal neovascularization (CNV) is a pathological process involving new blood vessel growth in the cornea.
  • Peroxisome proliferator-activated receptor alpha (PPARα) is a nuclear receptor involved in lipid metabolism and inflammation.
  • Fenofibrate, a PPARα agonist, is clinically used for lipid regulation.

Purpose of the Study:

  • To investigate the mechanism by which keratocytes inhibit corneal neovascularization (CNV) through PPARα activation.
  • To determine the role of PPARα in regulating VEGFr3 and MMP13 expression during CNV.

Main Methods:

  • Established a mouse model of CNV using alkali burn.
  • Administered fenofibrate or vehicle to CNV mice and analyzed corneal tissue.
  • Utilized quantitative RT-PCR (qRT-PCR) and Western blot (WB) to assess gene and protein expression (PPARα, VEGFr3, MMP13).
  • Performed immunohistochemistry to localize PPARα expression.
  • Investigated fenofibrate's effects on primary cultured keratocytes.
  • Utilized PPARα knockout (PPARα-/-) mice to confirm findings.

Main Results:

  • PPARα expression was decreased in corneas during CNV formation.
  • Fenofibrate treatment upregulated PPARα and downregulated VEGFr3 and MMP13, reducing CNV area.
  • Inhibition of PPARα in knockout models reversed these effects.
  • Fenofibrate's effects were consistent in both in vivo and in vitro keratocyte models.

Conclusions:

  • Keratocytes play a role in CNV formation.
  • PPARα downregulation in keratocytes promotes CNV by increasing VEGFr3 and MMP13 expression.
  • PPARα activation, potentially via fenofibrate, represents a therapeutic strategy for inhibiting CNV.